Drug Trial Radar · NCT02384538
A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Aug 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Mar 2015
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of ABT-981 to placebo in subjects with erosive hand osteoarthritis.
Conditions
- Erosive Hand Osteoarthritis
Interventions
ABT-981Biological
ABT-981 administered by subcutaneous injection
Placebo for ABT-981Biological
Placebo for ABT-981 administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16Time frame: Week 0 (Baseline), Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.